Sana Biotechnology, Inc. · NASDAQ:SANA
Sana Biotechnology — Investor Presentation (January 2026)
29 slides from Sana Biotechnology's investor presentation, Jan 14, 2026
Slide 1: Corporate Presentation January 2026
Corporate Presentation January 2026 Exhibit 99.1
Slide 2: Cautionary note regarding forward-looking statements
This presentation contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this presentation, including, among others, statements r
Slide 3: Changing the Possible for Patients
Type 1 diabetes represents a significant opportunity with validated biology ~10M people WW live with type 1 diabetes; current standard treatment remains exogenous insulin Disease impact remains significant, and patients want new alternatives Sana made significant progress in 2025 with immune evasion
Slide 4: Type 1 diabetes is a significant unmet need
~10M people WW with T1D; almost 2M in U.S. alone1 Etiology: autoimmune destruction of insulin-producing pancreatic beta cells Insulin replacement therapy is not curative, and patients need something better With the best current care (automated insulin pumps and continuous glucose monitoring), life e
Slide 5: T1D is a disease of missing pancreatic beta cells
T1D is a disease of missing pancreatic beta cells Advancing toward a cure for broad T1D population Primary islet transplants provide long-term glucose control, but: Supply is an issue Requires chronic immunosuppression 1 Stem-cell derived islets provide a scalable supply, but: Requires chronic immun
Slide 6: Overcoming allogeneic immune rejection has been key limitation in transplant
Allogeneic cell rejection ~75 years of transplants – immune rejection remains the largest problem Lifelong immunosuppression is current standard Genome modification efforts to date have generally been incomplete Autologous therapies have limited scalability and are only available for a small number
Slide 7: Sana has pioneered hypoimmune technology
Sana has pioneered hypoimmune technology
Slide 8: Clinical validation of hypoimmune islet cells in T1D patient without immunosuppression
Transplant into T1D patient without immunosuppression HIP gene modification of islet cells Donor cadaveric islet cells 1 2 3 Safety Immune evasion Cell survival Key Measured Outcomes Allogeneic, primary human HIP islet cell transplantation in type 1 diabetes patient Intramuscular administration in f
Slide 9: UP421 continues to evade immune detection and function without adverse events
UP421 continues to evade immune detection and function without any therapy-related adverse events All primary and secondary endpoints met Endpoints Wk 1 Wk 2 Wk 3 Wk 4 Wk 6 Wk 8 Wk 12 Wk 16/18 Wk 26 Wk 39 Wk 52 Safety (no AE/SAE related to drug) Cell survival/function (C-peptide) Graft visibility (M
Slide 10: HIP islet cell survival and function through at least one year
Basal C-peptide in peripheral blood HIP islet cell survival and function through at least one year Baseline: Below limit of detection (LOD).Sensitivity: 0.48 pmol/L. Dots represent technical triplicates. C-peptide analyzed in serum. Abbreviations: MMTT, mixed meal tolerance test. Increase in C-pepti
Slide 11: MRI and PET/MRI: further evidence of graft survival
Week 12 Week 52 Week 12 and 52 PET/MRI: further evidence of graft survival MR T2-STIR-weighted trans images showing signal in m. brachioradialis after injection of UP421 Uptake of Exendin-4 tracer specific for GLP-1R positive cells Graft Muscle Abbreviations: GLP-1R, glucagon-like peptide-1 receptor
Slide 12: No detectable immune response toward HIP islet cells at 12 months
Wild-type cells Result: cell killing MHC Class I/II K/O cells Result: cell killing Fully HIP-modified cells: Result: no cell killing No detectable immune response toward HIP islet cells at 12 months Abbreviation: PBMC, peripheral blood mononuclear cells; K/O, knock-out Summary: No killing of HIP-mod
Slide 13: SC451: developing for the broad T1D population
SC451: developing for the broad T1D population Make hypoimmune islet cells from stem cells 1 + CD47 MHC I MHC II Manufacture at scale 2 Deliver as a single therapy 3 SC451 program – HIP stem cell-derived islet cell therapy delivered with no immunosuppression Goal is to file IND and begin Phase 1 tri
Slide 14: Significant progress in 2025 turning science into a medicine
01. Clinical data UP421 03. Regulatory Dialogues with global regulators 02. Manufacturing Completed GMP master cell bank and working cell bank production Tech transfer started Scale-up work 04. Clinical planning Preclinical testing ongoing Defined target population for clinical trial Initial dialogu
Slide 15: SC451: next steps for value creation
SC451: next steps for value creation Complete GLP toxicology study & non-clinical testing package Complete GMP tech transfer & manufacture clinical trial material Make significant progress on commercial scale manufacturing process File IND and equivalent in at least one other geography Begin Phase 1
Slide 16: SC451 Phase 1 has clear definitions of success
Early immune evasion Endogenous insulin production evident within first month Potential for insulin independence within 3-6 months SC451 Phase 1 has clear definitions of success: safety, cell survival, and function D7 D0 D28 SC451 transplantation Up to Y5 Y2 M12 Active follow-up (year 1) Active foll
Slide 17: Fusosome technology: cell-specific in vivo delivery
Fusosome technology: cell-specific in vivo delivery F G Fusosome Sana approach: Leverage insights from nature to deliver various payloads to specific cells without lymphodepletion
Slide 18: In vivo engineering of CAR T cells using a fusosome vector system
Target cell killing CAR T cell amplification Delivery Transduction of CD8 T cells Expression Transgene integration & CAR expression Function Targeted cell killing T cell Fusosome B cell/tumor CAR T cell Transgene for CAR expression CAR CAR Sana is pursuing in vivo engineering of CAR T cells using a
Slide 19: Critical assumptions in developing this program
Lowers risk of off-target toxicity Lowers immunogenicity risk, potentially improving safety, persistence, and ability to re-dose Improves manufacturability CAR T cells typically undergo multi-logarithmic expansion inside the patient in order to clear target cells Integrated DNA replicates with cell
Slide 20: SG299 leads to potent transduction of circulating CD8+ cells
Fusogen has cross-reactivity with NHP CD8 CD19 CAR does not cross react with NHP CD19 Therefore, excellent model for PK, but not PD 4 NHP at each dose received single injection GLP Tox Study: SG299 leads to potent transduction of circulating CD8+ cells (~15-20%) Potent transduction of circulating CD
Slide 21: SG299 is specific for CD8+ cells; no off-target transduction
4 NHP at each dose received single injection GLP Tox Study: SG299 is specific for CD8+ cells; no transduction detected in hepatocytes or gonadal tissue NO LIVER OFF-TARGET NO TESTIS OFF-TARGET VCN is a sensitive marker for transduction Abbreviations: VCN, vector copy number.
Slide 22: CD8 T cell transduction with high on-target specificity
CD8 T cell transduction with high on-target specificity T cell restriction factors identified as limiting potency in resting T cells 2024-2025: Improved the platform to increase potency and probability of success Potent transduction of resting T cells in vivo resulting in CD19 CAR T cells that expan
Slide 23: SG293: next generation in vivo CAR T
SG293: next generation in vivo CAR T with improved potency and manufacturability SG293 Novel fusogen to increase gene delivery and reduce dose, while maintaining high specificity 1 Reduced CAR on vector particle to reduce immunogenicity and improve manufacturability 2 Incorporates an activation fact
Slide 24: SG293 incorporates novel fusogen with high specificity in vitro
SG293 incorporates novel fusogen with high specificity in vitro SG293 shows specificity for on-target vs. off-target cells in vitro compared to targeted VSV-G fusogen Cell Lines ON-target (CD8+) Low phagocytic activity High phagocytic activity
Slide 25: NHP study of SG293 surrogate in vivo
NHP study explored the efficacy, tolerability, and biodistribution of SG293 surrogate in vivo D-14 Multiple timepoints Necropsy (liver, spleen, etc.) Vehicle or Fusosome delivery (IV) In-process testing Pre-study baseline D0 D56 Study assessment overview General safety endpoints Clinical observation
Slide 26: Significant in vivo biologic activity demonstrated in NHP
Significant in vivo biologic activity demonstrated in NHP with SG293 surrogate BLQ: Below limit of quantitation Significant CAR T expansion in the blood Complete depletion of circulating B cells Lymph nodes at Week 3 Evidence of “reset” when B cells return Vec Ctrl NHP1 NHP2 Control NHP1 NHP2 Double
Slide 27: Fusogen platform potential for multiple best-in-class therapies
Sana’s fusogen platform has the potential for multiple best-in-class therapies SG293: Potential for initial clinical data in 2026 First trial likely in blood cancers With early safety & efficacy data, may be able to move rapidly into autoimmune diseases Recent progress creates potential for best-in-
Slide 28: Type 1 diabetes: a disease in need of better alternatives
Type 1 diabetes: a disease in need of better alternatives Scientific validation that a functional cure is possible SC451 assembles all components into a scalable platform 2026: Goal is to file IND & start Phase 1 trial Potential for early clinical proof of concept: Immune evasion Endogenous insulin
Slide 29: Thank You
Thank You Sana Biotechnology ( } ( | www.sana.com N Biotechnology
Sana Biotechnology — Investor Presentation (January 2026) on 6ix